Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on HCP

Share:
Related HCP
Argus Reaffirms Buy At HCP, Stock At 'Attractive' Levels
Stifel Weighs In On Healthcare REITs, Interest Rates & Top Picks
HCP, Inc.: This Problem Just Got Bigger (Seeking Alpha)

In a report published Friday, Jefferies & Company reiterated its Hold rating on HCP (NYSE: HCP), and slightly raised its price target from $45.00 to $46.00.

Jefferies noted, “We are updating our estimates for HCP and AMRE following announcements during the NAREIT conference in San Diego, CA. Our price target for HCP also increases to $46 from $45. See our accompanying note entitled ‘Tweets from NAREIT (November 2012 Edition)'.”

HCP closed on Thursday at $43.78.

Latest Ratings for HCP

DateFirmActionFromTo
Apr 2015BMO CapitalInitiates Coverage onUnderperform
Mar 2015UBSUpgradesNeutralBuy
Feb 2015Morgan StanleyDowngradesOverweightEqualweight

View More Analyst Ratings for HCP
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings

 

Related Articles (HCP)

Around the Web, We're Loving...